A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD

NCT ID: NCT01157715

Last Updated: 2014-11-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 122 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-05-31
• Study Completion Date: 2012-07-31

Brief Summary

This study is designed to access the safety and efficacy of multiple injections of KH902 at variable dosing regimens in patients with CNV due to neovascular AMD.

Detailed Description

AMD is the leading cause of severe vision loss in people over the age of 65 in the United States and other western countries. A quantity of documents indicate that neovascularization promoted by VEGF is main cause of visual acuity decline. Patients are starving for a new drug which can notably improve VA with less administration frequency and lower treatment cost.

The new drug Recombinant Human VEGF Receptor-Fc Fusion Protein (KH902) is a gene fusion protein. The pre-clinical researches and phase I study show that KH902 is effective and safe in inhibiting the growth, migration, pullulation of vascular endothelial cells and neovascularization induced by VEGF.

This study is designed to confirm the efficacy and safety of multiple injections of KH902 at variable dosing regimen in patients with CNV due to neovascular AMD. Based on the characteristics of KH902 and results from KH902 Phase I study as well as reference to clinical trials of similar drugs, it is determined that KH902 is administrated at 0.5mg/eye/time and 2.0mg/eye/time.

Conditions

Neovascular Age-related Macular Degeneration

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

0.5 mg cohort

patients will receive monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .

Group Type: EXPERIMENTAL

intravitreal injection of KH902

Intervention Type: BIOLOGICAL

2.0 mg cohort

patients will receive monthly intravitreal injections of 2.0 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .

Group Type: EXPERIMENTAL

intravitreal injection of KH902

Intervention Type: BIOLOGICAL

Interventions

intravitreal injection of KH902

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Signed the ICF; Age ≥ 50 years of either gender;
• Active primary or recurrent lesions with subfoveal or juxtafoveal CNV secondary to neovascular AMD in the study eye;
• Lesion size ≤ 12 disc areas in either eye;
• BCVA of the study eyes between 73 and 24 letters, inclusively, and the BCVA of fellow eyes ≥ 19 letters;
• Clear ocular media and adequate pupil dilation.
• If both eyes were eligible, only one was selected.

Exclusion Criteria

• History of vitreous hemorrhage, retinal detachment or macular hole, presence of retinal pigment epithelial tear, retinal macular traction or macular epiretinal membrane in the study eye;
• Subfoveal scar or atrophy in the study eye;
• Subretinal hemorrhage in the study eye;
• Uncontrolled glaucoma in either eye;
• Active inflammation or infection in either eye;
• Previous drug treatment, either anti-VEGF drugs or steroid derivatives, and/or, previous ophthalmologic operation or laser therapy in the study eye;
• History of surgery within one month preceding enrollment;
• Any uncontrolled clinical disorders;
• Patients of child-bearing potential do not adopted adequate contraception methods;
• Pregnant or nursing women;
• Patients need to exclude in the opinion of investigator.

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing DMS Pharma Ltd.

UNKNOWN

Sponsor Role: collaborator

The Digital Angiography Reading Center (DARC)

UNKNOWN

Sponsor Role: collaborator

Chengdu Kanghong Biotech Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xiaoxin Li, MD, Prof.

Role: PRINCIPAL_INVESTIGATOR

Peking University People's Hospital

Locations

Optometry and Ophthalmology Hospital of Wenzhou Medical College

Wenzhou, Fujian, China

Zhongshan Ophthalmic Center, Sun-Yat University

Guangzhou, Guangdong, China

Second Affiliated Hospital of Xiangya Medical College

Changsha, Hunan, China

Xijing Hosiptal of the Fourth Military Medical University

Xian, Shanxi, China

Sichuan University West China Hospitcal

Chengdu, Sichuan, China

Peking University People's Hospital

Beijing, , China

PekingTongren Hospital

Beijing, , China

Eye & ENT Hospital of Fudan University

Shanghai, , China

Shanghai First People's Hospital

Shanghai, , China

Countries

China

Other Identifiers

KHSWKH902001

Identifier Type: -

Identifier Source: org_study_id